These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 384070)

  • 1. Angiotensin as a renal, adrenal, and cardiovascular hormone: responses to saralasin in normal man and in essential and secondary hypertension.
    Hollenberg NK; Williams GH
    Kidney Int Suppl; 1979 Mar; (9):S29-35. PubMed ID: 384070
    [No Abstract]   [Full Text] [Related]  

  • 2. Physiologic studies with saralasin in animals.
    Gavras H; Gavras I; Brunner HR; Liang CS
    Kidney Int Suppl; 1979 Mar; (9):S20-8. PubMed ID: 384069
    [No Abstract]   [Full Text] [Related]  

  • 3. The adrenal receptor for angiotensin II is altered in essential hypertension.
    Williams GH; Hollenberg NK; Moore TJ; Swartz SL; Dluhy RG
    J Clin Invest; 1979 Mar; 63(3):419-27. PubMed ID: 219037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saralasin in human hypertension: the early experience.
    Brunner HR; Laragh JH
    Kidney Int Suppl; 1979 Mar; (9):S36-43. PubMed ID: 289862
    [No Abstract]   [Full Text] [Related]  

  • 5. [SAR1, ALA8]-Angiotensin II (saralasin): a symposium. Introduction.
    Vaughan ED; Peach MJ
    Kidney Int Suppl; 1979 Mar; (9):S1-2. PubMed ID: 289858
    [No Abstract]   [Full Text] [Related]  

  • 6. Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.
    Hollenberg NK; Williams GH; Burger B; Ishikawa I; Adams DF
    J Clin Invest; 1976 Jan; 57(1):39-46. PubMed ID: 1245602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saralasin infusion in renovascular and essential hypertension.
    Thien T; Hoefnagels WH
    Neth J Med; 1980; 23(2):68-73. PubMed ID: 6990282
    [No Abstract]   [Full Text] [Related]  

  • 9. Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade.
    Laragh JH; Case DB; Wallace JM; Keim H
    Fed Proc; 1977 Apr; 36(5):1781-7. PubMed ID: 191300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Saralasin for renovascular or essential hypertension (author's transl)].
    Arlart I; Rosenthal J
    Dtsch Med Wochenschr; 1978 Nov; 103(45):1790-6. PubMed ID: 710289
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical pharmacology of saralasin.
    Castellion AW; Fulton RW
    Kidney Int Suppl; 1979 Mar; (9):S11-9. PubMed ID: 113608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immediate pressor response to saralasin: a measure of the degree of angiotensin II vascular receptor vacancy.
    Wallace JM; Case DB; Laragh JH; Sealey JE; Keim HJ; Drayer JI
    Trans Assoc Am Physicians; 1977; 90():300-12. PubMed ID: 205983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient experience with saralasin.
    Streeten DH; Anderson GH
    Kidney Int Suppl; 1979 Mar; (9):S44-52. PubMed ID: 289863
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance.
    Brunner HR; Gavras H; Ribeiro AB; Posternak L
    Prog Biochem Pharmacol; 1976; 12():145-62. PubMed ID: 1019161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension.
    Dluhy RG; Bavli SZ; Leung FK; Solomon HS; Moore TJ; Hollenberg NK; Williams GH
    J Clin Invest; 1979 Nov; 64(5):1270-6. PubMed ID: 500810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II blockade by saralasin in the evaluation of hypertension in children.
    Favre L; Boerth RC; Braren V; Dean RH; Hollifield JW
    Kidney Int Suppl; 1979 Mar; (9):S75-82. PubMed ID: 289867
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of saralasin on plasma aldosterone in hypertensive man.
    Brown RD; Tucker R; Tue K; Wisgerhof M; Salassa R
    J Lab Clin Med; 1978 Mar; 91(3):473-9. PubMed ID: 627750
    [No Abstract]   [Full Text] [Related]  

  • 18. Saralasin (1-sar-8-ala-angiotensin II): pharmacology and clinical use in angiotensin-dependent hypertension.
    Streeten DH; Castellian AW; Micalizzi ER; Dalakos TG; Anderson GH; Freiberg JM; Keenan RE
    Contrib Nephrol; 1976; 3():52-70. PubMed ID: 1026370
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of high sodium intake and angiotensin antagonist in rabbits with severe and moderate hypertension induced by constriction of one renal artery.
    Romero JC; Holmes DR; Strong CG
    Circ Res; 1977 May; 40(5 Suppl 1):I17-23. PubMed ID: 870227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adrenal arterial infusion of saralasin (P113) on aldosterone secretion.
    Blair-West JR; Coghlan JP; Denton DA; Niall HD; Scoggins BA; Tregear GW
    Prog Biochem Pharmacol; 1976; 12():53-62. PubMed ID: 1019170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.